CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 40 target
Drug / intervention
nanoparticle albumin-bound paclitaxel +2 moredrug
Likely dose
nanoparticle albumin-bound paclitaxel 125 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03636308
NCT03636308Phase 2Unknown
CompareCT.gov

Phase II Trial Comparing Nab-paclitaxel Plus S-1 Versus Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Patients With Advanced Pancreatic Cancer

Peking University·interventional·Posted Aug 17, 2018·Updated Aug 17, 2018

In Brief

A Phase 2 clinical trial evaluating nanoparticle albumin-bound paclitaxel, S1, and 1 other intervention for Pancreatic Cancer. Targeting 40 participants across 1 site.

Detailed Summary

This is a randomized phase II trial comparing the first-line treatment with nab-paclitaxel plus S-1(AS) and nab-paclitaxel plus gemcitabine(AG) in advanced pancreatic ductal adenocarcinoma (PDA) with primary tumor nonexcision in Chinese patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
20192020202120222023202420252026
First PostedAug 17, 2018
Enrollment StartJul 17, 2018
Primary CompletionAug 1, 2020
Study CompletionAug 1, 2021
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 7.9 years ago

Interventions

nanoparticle albumin-bound paclitaxeldrug

Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.

S1drug

S-1 is orally administered (BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle.

Gemcitabinedrug

Gemcitabine is given at 1000mg/m2 intravenously on d1 and 8 of each 21 day cycle.